AR076030A1 - Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso - Google Patents
Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de usoInfo
- Publication number
- AR076030A1 AR076030A1 ARP100101080A ARP100101080A AR076030A1 AR 076030 A1 AR076030 A1 AR 076030A1 AR P100101080 A ARP100101080 A AR P100101080A AR P100101080 A ARP100101080 A AR P100101080A AR 076030 A1 AR076030 A1 AR 076030A1
- Authority
- AR
- Argentina
- Prior art keywords
- hvr
- sequence
- seq
- methods
- immunocate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud se refiere a composiciones del tema utiles para el tratamiento del tumor hematopoyético en los mamíferos y a los métodos que usan estas composiciones para lo mismo. Reivindicacion 1: Un anticuerpo anti-FcRH5 que comprende: (a) al menos una secuencia de HVR seleccionada del grupo que consiste en: (i) HVR-L1 que comprende la secuencia KASQNVGSNVA (SEQ ID Ns:28), (ii) HVR-L2 que comprende la secuencia SASYRYS (SEQ ID Ns:29), (iii) HVR-L3 que comprende la secuencia QQYKTWT (SEQ ID Ns:30), (iv) HVR-H1 que comprende la secuencia GYTFTNYGMN (SEQ ID Ns:37), (v) HVR-H2 que comprende la secuencia NTYTGEPTYTDDFKG (SEQ ID Ns:38), (vi) HVR-H3 que comprende la secuencia ARRSIPYYYAMDY (SEQ ID Ns:39); y (b) al menos una variante de HVR, en donde la variante de HVR comprende la modificacion de al menos un residuo de la secuencia descripta en la SEQ ID Ns: 28, 29, 30, 37, 38 o 39.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21175409P | 2009-04-01 | 2009-04-01 | |
| US16621409P | 2009-04-02 | 2009-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076030A1 true AR076030A1 (es) | 2011-05-11 |
Family
ID=42236394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101080A AR076030A1 (es) | 2009-04-01 | 2010-03-31 | Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8362213B2 (es) |
| EP (1) | EP2414395A1 (es) |
| JP (2) | JP6099976B2 (es) |
| KR (1) | KR20120003478A (es) |
| CN (1) | CN102369218B (es) |
| AR (1) | AR076030A1 (es) |
| AU (1) | AU2010232682A1 (es) |
| BR (1) | BRPI1012560A2 (es) |
| CA (1) | CA2756988A1 (es) |
| CL (1) | CL2011002418A1 (es) |
| IL (1) | IL215404A0 (es) |
| MX (1) | MX2011010265A (es) |
| PE (1) | PE20120877A1 (es) |
| RU (2) | RU2016110891A (es) |
| SG (1) | SG174930A1 (es) |
| TW (1) | TW201039846A (es) |
| WO (1) | WO2010114940A1 (es) |
| ZA (1) | ZA201107128B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120003478A (ko) | 2009-04-01 | 2012-01-10 | 제넨테크, 인크. | 항-ＦｃＲＨ5 항체 및 면역접합체 및 사용 방법 |
| TW201038286A (en) | 2009-04-01 | 2010-11-01 | Genentech Inc | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| BR112013030372A2 (pt) * | 2011-05-27 | 2016-08-30 | Ambrx Inc | composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural |
| TWI603741B (zh) | 2011-06-10 | 2017-11-01 | 梅爾莎納醫療公司 | 蛋白質-聚合物-藥物共軛體 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| CA2900755C (en) * | 2013-02-08 | 2021-07-20 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| WO2014157704A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| DK2982681T3 (en) | 2013-03-29 | 2018-12-10 | Sumitomo Dainippon Pharma Co Ltd | WT1 ANTIGENPEPTIDKONJUGATVACCINE |
| TWI725931B (zh) * | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| JP6208864B2 (ja) * | 2013-06-24 | 2017-10-04 | エービーエルバイオ | 安定性が改善された抗体−薬物結合体およびこれの用途 |
| ES2754397T3 (es) | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
| ES2726850T3 (es) | 2013-10-11 | 2019-10-09 | Mersana Therapeutics Inc | Conjugados de proteína-polímero-fármaco |
| KR20220116581A (ko) | 2013-12-17 | 2022-08-23 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| WO2016040868A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
| CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| AU2015357543B2 (en) | 2014-12-05 | 2021-10-21 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof |
| CN108064246A (zh) * | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| RS64662B1 (sr) * | 2015-06-16 | 2023-11-30 | Hoffmann La Roche | Humanizovana i afinitetno sazrela antitela na fcrh5 i postupci upotrebe |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| WO2017096120A1 (en) | 2015-12-04 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and methods of use |
| JPWO2017188346A1 (ja) * | 2016-04-27 | 2019-02-28 | 国立大学法人 東京大学 | マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法 |
| KR20230082055A (ko) * | 2016-06-17 | 2023-06-08 | 마젠타 테라퓨틱스 인코포레이티드 | 세포의 고갈을 위한 조성물 및 방법 |
| KR20190074300A (ko) | 2016-11-15 | 2019-06-27 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
| WO2018101309A1 (ja) | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| MX2019015057A (es) * | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| JP7407699B2 (ja) | 2017-07-28 | 2024-01-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体製剤 |
| WO2019031615A1 (ja) * | 2017-08-10 | 2019-02-14 | 大日本住友製薬株式会社 | ヘミアスタリン誘導体及びこれらの抗体薬物複合体 |
| TWI805602B (zh) * | 2017-08-10 | 2023-06-21 | 日商住友製藥股份有限公司 | 包含半星芒體衍生物之抗體藥物複合體 |
| US10766613B2 (en) * | 2017-11-28 | 2020-09-08 | Textron Innovations Inc. | System and method for rotorcraft-weight-on-wheels flight state transition control |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| WO2019157308A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
| CA3093295A1 (en) | 2018-03-06 | 2019-09-12 | Imcare Biotech, Llc | Serine protease inhibitor kazal (spik) compositions and methods |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US12247245B2 (en) | 2018-07-25 | 2025-03-11 | Northeastern University | Selectivity screening for antimicrobial compounds |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US12178879B2 (en) | 2019-02-13 | 2024-12-31 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivative and antibody-drug conjugate thereof |
| JP7560255B2 (ja) * | 2019-02-13 | 2024-10-02 | 住友ファーマ株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
| CN113412271B (zh) | 2019-02-13 | 2024-10-22 | 住友制药株式会社 | 具有半胱氨酸残基的哈米特林衍生物 |
| MX2021009764A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| CN114174341A (zh) * | 2019-07-08 | 2022-03-11 | 英凯尔生物科技有限责任公司 | 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法 |
| KR20220080098A (ko) | 2019-09-11 | 2022-06-14 | 아임케어 바이오테크, 엘엘씨. | 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프 |
| PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
| EP4077391A1 (en) | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CN116368154A (zh) | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
| AU2021374592A1 (en) | 2020-11-04 | 2023-06-01 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP4240493A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| WO2022098628A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| US20240384293A1 (en) | 2021-04-27 | 2024-11-21 | Novartis Ag | Viral vector production system |
| IL306111A (en) | 2021-04-30 | 2023-11-01 | Hoffmann La Roche | Dosage for combined treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody and anti-CD79B antibody for antiretroviral drugs |
| IL308417A (en) | 2021-05-14 | 2024-01-01 | Genentech Inc | Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
| CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| AR129062A1 (es) * | 2022-04-13 | 2024-07-10 | Genentech Inc | Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso |
| AU2023254206A1 (en) | 2022-04-13 | 2024-10-17 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| EP4608983A1 (en) | 2022-10-26 | 2025-09-03 | Novartis AG | Lentiviral formulations |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN116199772B (zh) * | 2022-11-16 | 2023-10-17 | 怡道生物科技(苏州)有限公司 | Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用 |
| WO2025235357A1 (en) | 2024-05-06 | 2025-11-13 | Rondo Therapeutics, Inc. | Bispecific antibodies that bind to cd28 and nectin-4 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US20030054987A1 (en) | 1997-06-16 | 2003-03-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| ES2568625T3 (es) * | 1999-11-29 | 2016-05-03 | The Trustees Of Columbia University In The City Of New York | Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma |
| US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002329540A1 (en) * | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| NZ531674A (en) | 2001-09-18 | 2009-03-31 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス，インコーポレーテッド | 抗ｃｄ３０抗体を使用する免疫学的疾患の治療 |
| WO2004032828A2 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| NZ547633A (en) | 2003-11-06 | 2010-08-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| CA2551813C (en) | 2003-12-24 | 2014-08-12 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2006039238A2 (en) * | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| EP1846449A4 (en) | 2005-01-12 | 2009-07-08 | Medarex Inc | IRTA-2 ANTIBODIES AND THEIR USE |
| KR100970824B1 (ko) * | 2005-06-20 | 2010-07-16 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
| WO2008109533A2 (en) * | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
| KR20120003478A (ko) | 2009-04-01 | 2012-01-10 | 제넨테크, 인크. | 항-ＦｃＲＨ5 항체 및 면역접합체 및 사용 방법 |
| TW201038286A (en) | 2009-04-01 | 2010-11-01 | Genentech Inc | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
-
2010
- 2010-03-31 KR KR1020117025849A patent/KR20120003478A/ko not_active Abandoned
- 2010-03-31 WO PCT/US2010/029521 patent/WO2010114940A1/en not_active Ceased
- 2010-03-31 US US12/751,791 patent/US8362213B2/en not_active Expired - Fee Related
- 2010-03-31 AR ARP100101080A patent/AR076030A1/es not_active Application Discontinuation
- 2010-03-31 BR BRPI1012560A patent/BRPI1012560A2/pt not_active IP Right Cessation
- 2010-03-31 CA CA2756988A patent/CA2756988A1/en not_active Abandoned
- 2010-03-31 PE PE2011001751A patent/PE20120877A1/es not_active Application Discontinuation
- 2010-03-31 CN CN201080014347.1A patent/CN102369218B/zh not_active Expired - Fee Related
- 2010-03-31 TW TW099109950A patent/TW201039846A/zh unknown
- 2010-03-31 RU RU2016110891A patent/RU2016110891A/ru not_active Application Discontinuation
- 2010-03-31 JP JP2012503682A patent/JP6099976B2/ja not_active Expired - Fee Related
- 2010-03-31 EP EP10711526A patent/EP2414395A1/en not_active Ceased
- 2010-03-31 AU AU2010232682A patent/AU2010232682A1/en not_active Abandoned
- 2010-03-31 SG SG2011069895A patent/SG174930A1/en unknown
- 2010-03-31 MX MX2011010265A patent/MX2011010265A/es active IP Right Grant
- 2010-03-31 RU RU2011144119/10A patent/RU2583270C2/ru not_active IP Right Cessation
-
2011
- 2011-09-27 IL IL215404A patent/IL215404A0/en unknown
- 2011-09-29 ZA ZA2011/07128A patent/ZA201107128B/en unknown
- 2011-09-30 CL CL2011002418A patent/CL2011002418A1/es unknown
-
2012
- 2012-11-09 US US13/673,565 patent/US9017951B2/en not_active Expired - Fee Related
-
2015
- 2015-08-27 JP JP2015168182A patent/JP2016028052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9017951B2 (en) | 2015-04-28 |
| WO2010114940A1 (en) | 2010-10-07 |
| TW201039846A (en) | 2010-11-16 |
| HK1166805A1 (en) | 2012-11-09 |
| BRPI1012560A2 (pt) | 2016-07-26 |
| CN102369218A (zh) | 2012-03-07 |
| JP6099976B2 (ja) | 2017-03-29 |
| PE20120877A1 (es) | 2012-08-06 |
| KR20120003478A (ko) | 2012-01-10 |
| RU2016110891A (ru) | 2018-11-27 |
| CN102369218B (zh) | 2014-07-16 |
| ZA201107128B (en) | 2012-12-27 |
| US20130089497A1 (en) | 2013-04-11 |
| US20110171125A1 (en) | 2011-07-14 |
| JP2016028052A (ja) | 2016-02-25 |
| CL2011002418A1 (es) | 2012-03-16 |
| CA2756988A1 (en) | 2010-10-07 |
| EP2414395A1 (en) | 2012-02-08 |
| SG174930A1 (en) | 2011-11-28 |
| MX2011010265A (es) | 2011-10-11 |
| IL215404A0 (en) | 2011-12-29 |
| AU2010232682A1 (en) | 2011-11-10 |
| RU2583270C2 (ru) | 2016-05-10 |
| US8362213B2 (en) | 2013-01-29 |
| JP2012522513A (ja) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076030A1 (es) | Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso | |
| AR076029A1 (es) | Anticuerpos anti- fcrh5 (receptor de translocacion asociado a la superfamilia de inmunoglobulina) e inmunoconjugados y metodos de uso | |
| AR067543A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso | |
| AR067544A1 (es) | Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos | |
| ES2628108T3 (es) | Anticuerpos multiespecíficos | |
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
| PE20141722A1 (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t | |
| WO2013003680A8 (en) | Anti-c-met antibody formulations | |
| RU2011134500A (ru) | Антитела и иммуноконъюгаты и их применения | |
| AR084456A1 (es) | Anticuerpo anti-pcsk9 y metodos de uso | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| CO6220835A2 (es) | Anticuerpos anti-robo4 y sus usos | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
| AR096364A1 (es) | Anticuerpos receptores de antitransferina y métodos de uso | |
| PE20150211A1 (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| PE20141114A1 (es) | Anticuerpos anti-mesotelina e inmunoconjugados | |
| MX387662B (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| PE20120080A1 (es) | Anticuerpos anti-notch2 y metodos de uso | |
| AR059432A1 (es) | Anticuerpos anti-fgf19 y metodos que usan estos | |
| AR076662A1 (es) | Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos | |
| IL290591B1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| CO6331344A2 (es) | Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |